Overview

Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
- To evaluate the superiority in the efficacy of HMR1964 and OHA combination therapy as compared with OHA therapy. - To evaluate the superiority in the efficacy of HMR1964 mono-therapy as compared with OHA therapy. - To evaluate the safety of HMR1964.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Insulin
Insulin glulisine
Insulin, Globin Zinc